MARKET

TRVN

TRVN

Trevena
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5100
+0.0001
+0.02%
After Hours: 0.5300 +0.02 +3.92% 18:05 04/09 EDT
OPEN
0.5033
PREV CLOSE
0.5099
HIGH
0.5300
LOW
0.5000
VOLUME
1.18M
TURNOVER
--
52 WEEK HIGH
1.650
52 WEEK LOW
0.4600
MARKET CAP
49.84M
P/E (TTM)
-1.8826
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TRVN stock price target is 3.750 with a high estimate of 4.000 and a low estimate of 3.500.

EPS

TRVN News

More
  • Trevena Enters Oversold Territory
  • Zacks · 2d ago
  • Edited Transcript of TRVN earnings conference call or presentation 12-Mar-20 12:00pm GMT
  • Thomson Reuters StreetEvents · 03/30 09:37
  • Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/12 15:15
  • Trevena Reports Fourth Quarter and Full Year 2019 Results
  • GlobeNewswire · 03/12 12:01

Industry

Biotechnology & Medical Research
+1.63%
Pharmaceuticals & Medical Research
+0.82%

Hot Stocks

Symbol
Price
%Change

About TRVN

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
More

Webull offers kinds of Trevena Inc stock information, including NASDAQ:TRVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVN stock news, and many more online research tools to help you make informed decisions.